AQR Capital Management LLC Purchases 26,144 Shares of Penumbra, Inc. (NYSE:PEN)

AQR Capital Management LLC lifted its stake in Penumbra, Inc. (NYSE:PEN - Free Report) by 19.6% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 159,435 shares of the company's stock after purchasing an additional 26,144 shares during the period. AQR Capital Management LLC owned 0.42% of Penumbra worth $37,863,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Baillie Gifford & Co. grew its holdings in shares of Penumbra by 23.4% in the 4th quarter. Baillie Gifford & Co. now owns 730,233 shares of the company's stock valued at $173,416,000 after buying an additional 138,387 shares during the period. T. Rowe Price Investment Management Inc. increased its position in shares of Penumbra by 47.4% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 707,061 shares of the company's stock worth $167,913,000 after acquiring an additional 227,506 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in Penumbra by 23.1% in the 4th quarter. Dimensional Fund Advisors LP now owns 323,964 shares of the company's stock valued at $76,937,000 after acquiring an additional 60,764 shares in the last quarter. Franklin Resources Inc. boosted its stake in Penumbra by 8.2% in the 3rd quarter. Franklin Resources Inc. now owns 319,232 shares of the company's stock worth $67,473,000 after purchasing an additional 24,091 shares during the period. Finally, Northern Trust Corp lifted its holdings in shares of Penumbra by 20.8% in the fourth quarter. Northern Trust Corp now owns 318,230 shares of the company's stock valued at $75,573,000 after purchasing an additional 54,890 shares in the last quarter. Institutional investors own 88.88% of the company's stock.

Insider Buying and Selling

In related news, Director Thomas Wilder sold 360 shares of Penumbra stock in a transaction on Monday, March 31st. The shares were sold at an average price of $264.58, for a total value of $95,248.80. Following the transaction, the director now directly owns 4,533 shares of the company's stock, valued at $1,199,341.14. The trade was a 7.36 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Maggie Yuen sold 2,000 shares of the firm's stock in a transaction on Friday, May 2nd. The stock was sold at an average price of $299.01, for a total transaction of $598,020.00. Following the completion of the sale, the chief financial officer now directly owns 13,957 shares in the company, valued at approximately $4,173,282.57. This trade represents a 12.53 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 142,446 shares of company stock valued at $40,141,973. 5.00% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the stock. Bank of America began coverage on shares of Penumbra in a research report on Friday, March 14th. They issued a "buy" rating and a $320.00 price objective on the stock. Truist Financial upped their price objective on Penumbra from $315.00 to $330.00 and gave the stock a "buy" rating in a research note on Thursday, April 24th. Stifel Nicolaus set a $318.00 target price on shares of Penumbra and gave the stock a "buy" rating in a report on Thursday, April 24th. Robert W. Baird lifted their price objective on shares of Penumbra from $316.00 to $325.00 and gave the company an "outperform" rating in a research report on Thursday, April 24th. Finally, Piper Sandler reiterated an "overweight" rating and issued a $330.00 target price (up from $250.00) on shares of Penumbra in a research note on Wednesday, February 19th. Three equities research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Penumbra currently has an average rating of "Moderate Buy" and a consensus target price of $302.40.

Penumbra Stock Up 1.3 %

Penumbra stock traded up $3.85 during midday trading on Thursday, reaching $293.10. The stock had a trading volume of 85,010 shares, compared to its average volume of 425,280. The company has a fifty day moving average price of $277.42 and a two-hundred day moving average price of $259.36. The company has a market capitalization of $11.35 billion, a P/E ratio of 863.73, a PEG ratio of 2.83 and a beta of 0.53. The company has a current ratio of 6.01, a quick ratio of 3.25 and a debt-to-equity ratio of 0.02. Penumbra, Inc. has a 12 month low of $148.00 and a 12 month high of $310.00.

Penumbra (NYSE:PEN - Get Free Report) last issued its quarterly earnings data on Wednesday, April 23rd. The company reported $0.83 EPS for the quarter, topping analysts' consensus estimates of $0.66 by $0.17. The firm had revenue of $324.14 million during the quarter, compared to analyst estimates of $315.72 million. Penumbra had a return on equity of 9.74% and a net margin of 1.17%. The company's revenue for the quarter was up 16.3% on a year-over-year basis. During the same period in the previous year, the company posted $0.41 EPS. As a group, equities analysts expect that Penumbra, Inc. will post 3.67 EPS for the current fiscal year.

Penumbra Company Profile

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.